JP2002508387A5 - - Google Patents

Download PDF

Info

Publication number
JP2002508387A5
JP2002508387A5 JP2000539042A JP2000539042A JP2002508387A5 JP 2002508387 A5 JP2002508387 A5 JP 2002508387A5 JP 2000539042 A JP2000539042 A JP 2000539042A JP 2000539042 A JP2000539042 A JP 2000539042A JP 2002508387 A5 JP2002508387 A5 JP 2002508387A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000539042A
Other languages
Japanese (ja)
Other versions
JP4413428B2 (ja
JP2002508387A (ja
Filing date
Publication date
Priority claimed from US08/991,743 external-priority patent/US6229002B1/en
Application filed filed Critical
Publication of JP2002508387A publication Critical patent/JP2002508387A/ja
Publication of JP2002508387A5 publication Critical patent/JP2002508387A5/ja
Application granted granted Critical
Publication of JP4413428B2 publication Critical patent/JP4413428B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000539042A 1997-12-16 1998-04-29 血小板由来増殖因子（ｐｄｇｆ）核酸リガンド複合体 Expired - Fee Related JP4413428B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/991,743 US6229002B1 (en) 1995-06-07 1997-12-16 Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US08/991,743 1997-12-16
PCT/US1998/009050 WO1999031119A1 (en) 1997-12-16 1998-04-29 Platelet derived growth factor (pdgf) nucleic acid ligand complexes

Publications (3)

Publication Number Publication Date
JP2002508387A JP2002508387A (ja) 2002-03-19
JP2002508387A5 true JP2002508387A5 (enExample) 2005-12-22
JP4413428B2 JP4413428B2 (ja) 2010-02-10

Family

ID=25537513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000539042A Expired - Fee Related JP4413428B2 (ja) 1997-12-16 1998-04-29 血小板由来増殖因子（ｐｄｇｆ）核酸リガンド複合体

Country Status (11)

Country Link
US (5) US6229002B1 (enExample)
EP (1) EP1042348B1 (enExample)
JP (1) JP4413428B2 (enExample)
AU (1) AU749273B2 (enExample)
CA (1) CA2315271C (enExample)
CY (1) CY1114352T1 (enExample)
DK (1) DK1042348T3 (enExample)
ES (1) ES2426160T3 (enExample)
PT (1) PT1042348E (enExample)
SI (1) SI1042348T1 (enExample)
WO (1) WO1999031119A1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6346611B1 (en) * 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US6465188B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US8071737B2 (en) * 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US6699843B2 (en) * 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US20060057573A1 (en) 2002-02-15 2006-03-16 Somalogic, Inc Methods and reagents for detecting target binding by nucleic acid ligands
EP2070968A3 (en) 1999-12-22 2013-07-24 Nektar Therapeutics Method for the Preparation of 1-Benzotriazolyl Carbonate Esters of Poly(ethylene glycol)
AU2001263251A1 (en) * 2000-05-17 2001-11-26 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to pdgf
WO2002036073A2 (en) * 2000-11-02 2002-05-10 Smithkline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
AU2002233619A1 (en) * 2001-02-26 2002-09-12 Zur Pierre Beserman Systems devices and methods for intrabody targeted delivery and reloading of therapeutic agents
IL159053A0 (en) 2001-05-25 2004-05-12 Univ Duke Modulators of pharmacological agents
AU2003247576A1 (en) * 2002-06-18 2003-12-31 Archemix Corp. Aptamer-toxin molecules and methods for using same
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
US20040110235A1 (en) * 2002-07-25 2004-06-10 David Epstein Regulated aptamer therapeutics
US20040253243A1 (en) * 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US8853376B2 (en) * 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20040180360A1 (en) * 2002-11-21 2004-09-16 Charles Wilson Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
US8039443B2 (en) * 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20090053138A1 (en) * 2002-11-21 2009-02-26 Preiss Jeffrey R Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology Therapeutics
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
EP1620547B1 (en) 2003-04-21 2014-06-18 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20040260034A1 (en) 2003-06-19 2004-12-23 Haile William Alston Water-dispersible fibers and fibrous articles
US8513147B2 (en) 2003-06-19 2013-08-20 Eastman Chemical Company Nonwovens produced from multicomponent fibers
US7892993B2 (en) 2003-06-19 2011-02-22 Eastman Chemical Company Water-dispersible and multicomponent fibers from sulfopolyesters
SI1660057T1 (sl) * 2003-08-27 2012-10-30 Ophthotech Corp Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti
ES2674129T3 (es) 2004-02-12 2018-06-27 Archemix Llc Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
EP1756138A4 (en) * 2004-03-05 2009-07-01 Archemix Corp HUMAN CYTOKINE FAMILY BINDING APTAMERS AND THEIR USE AS THERAPEUTIC AGENTS OF AUTOIMMUNE DISEASES
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US20080214489A1 (en) * 2004-04-19 2008-09-04 Anthony Dominic Keefe Aptamer-mediated intracellular delivery of oligonucleotides
US7579450B2 (en) * 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
CA2578046A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
MX2007002772A (es) 2004-09-07 2008-03-05 Archemix Corp Aptameros para el factor de von willebrand y su uso como agentes terapeuticos para la enfermedad trombotica.
EP1807107B1 (en) * 2004-11-02 2011-09-07 Archemix Corp. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
ATE418966T1 (de) * 2004-11-03 2009-01-15 Liplasome Pharma As Arzneimittelabgabesysteme auf lipidbasis mit unnatürlichen phospholipase-a2-abbaubaren lipid- derivaten und ihre therapeutische verwendung
DE502005009920D1 (de) * 2004-11-29 2010-08-26 Noxxon Pharma Ag Vasopressin bindende l-nukleinsäure
US8105813B2 (en) 2005-06-30 2012-01-31 Archemix Corp. Materials and methods for the generation of fully 2′-modified nucleic acid transcripts
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
US7922000B2 (en) * 2006-02-15 2011-04-12 Miraial Co., Ltd. Thin plate container with a stack of removable loading trays
DK1991275T3 (en) 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
WO2008134077A1 (en) * 2007-04-30 2008-11-06 Archemix Corp. Metabolic profile directed aptamer medicinal chemistry
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
US8207298B2 (en) * 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8512519B2 (en) 2009-04-24 2013-08-20 Eastman Chemical Company Sulfopolyesters for paper strength and process
JP2012525415A (ja) * 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
WO2010141771A1 (en) * 2009-06-03 2010-12-09 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein vi
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
US8841429B2 (en) 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
WO2012054668A2 (en) * 2010-10-21 2012-04-26 Useastman Chemical Company Sulfopolyester binders
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US8735367B2 (en) 2011-06-27 2014-05-27 University Of Utah Research Foundation Small molecule-dependent split aptamer ligation
CA2868096C (en) 2012-03-28 2019-12-31 Somalogic, Inc. Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN103290019B (zh) * 2013-06-14 2014-03-12 严鹏科 一种动脉粥样硬化的靶向适配子及其制备方法和应用
IL294463A (en) 2013-07-12 2022-09-01 Iveric Bio Inc Methods for treating or preventing eye conditions
JP6630273B2 (ja) 2013-09-09 2020-01-15 ソマロジック・インコーポレーテッド 安定性が向上したｐｄｇｆ及びｖｅｇｆアプタマー並びにｐｄｇｆ及びｖｅｇｆ媒介性の疾患及び障害の治療におけるそれらの使用
KR20160134738A (ko) 2014-03-17 2016-11-23 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 국소적 전달을 위한 압타머
MX2020003695A (es) 2017-11-30 2020-08-03 Arrakis Therapeutics Inc Fotosondas de union a acido nucleico y usos de las mismas.

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB462145A (en) 1934-11-19 1937-03-03 Albert Von Lom Improvements in or relating to drying plants
AU4434585A (en) 1985-03-30 1986-10-23 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
WO1989006694A1 (en) 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
JPH04503957A (ja) 1989-03-07 1992-07-16 ジェネンテク，インコーポレイテッド 脂質とオリゴヌクレオチドの共有結合コンジュゲート
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
WO1995006659A1 (en) 1992-07-01 1995-03-09 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
CA2079109A1 (en) 1990-03-29 1991-09-30 John A. Latham Oligonucleotide-transport agent disulfide conjugates
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
AU1435492A (en) 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
US5171217A (en) 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
CA2082411A1 (en) 1991-06-28 1992-12-29 Robert D. Rosenberg Localized oligonucleotide therapy
US6172208B1 (en) 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
US5756291A (en) * 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
US5631237A (en) * 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
IL108206A0 (en) 1993-01-06 1994-04-12 Univ Johns Hopkins Oligomers having improved stability at acid ph
EP0689465A1 (en) 1993-03-18 1996-01-03 Cedars-Sinai Medical Center Drug incorporating and releasing polymeric coating for bioprosthesis
WO1994027615A1 (en) 1993-05-26 1994-12-08 Genta Incorporated Oligomer conjugates and their use
WO1994029479A1 (en) 1993-06-09 1994-12-22 Pharmagenics, Inc. Oligonucleotides which inhibit hiv protease function
AU7175094A (en) 1993-06-18 1995-01-17 Pharmagenics, Inc. Inhibition of interferon-gamma with oligonucleotides
JPH09502354A (ja) 1993-09-08 1997-03-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンドと、同リガンドを製造するための改良された方法
AU692185B2 (en) 1993-09-17 1998-06-04 Somalogic, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5614503A (en) * 1993-11-12 1997-03-25 Aronex Pharmaceuticals, Inc. Amphipathic nucleic acid transporter
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
EP0824541B1 (en) 1995-05-04 2009-12-16 Gilead Sciences, Inc. Nucleic acid ligand complexes
US5723594A (en) * 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
JP4531132B2 (ja) * 1995-06-02 2010-08-25 ギリード・サイエンシズ・インコーポレーテッド 増殖因子に対する高親和性オリゴヌクレオチドリガンド

Similar Documents

Publication Publication Date Title
FR08C0038I1 (enExample)
JP2001519638A5 (enExample)
JP2001513393A5 (enExample)
JP2003517519A5 (enExample)
JP2002508387A5 (enExample)
IN192936B (enExample)
JP2001514030A5 (enExample)
BRPI9917862A2 (enExample)
BRPI9914151B8 (enExample)
JP2002500376A5 (enExample)
JP2001525207A5 (enExample)
JP3076551B6 (enExample)
BRPI9917863A2 (enExample)
IN186860B (enExample)
JP2527297Z (enExample)
JP2643250C (enExample)
JP2541338C (enExample)
JP2565959C (enExample)
JP2582019C (enExample)
IN190582B (enExample)
IN187158B (enExample)
CN3073190S (enExample)
CL1998003164A1 (enExample)
CN3081719S (enExample)
CN3074693S (enExample)